Isis announces 'positive' results from Phase 1 study with ISIS-APO Rx

theflyonthewall.com

Isis Pharmaceuticals announced positive results from a Phase 1 study with ISIS-APO Rx. These data were presented by Dr. Sotirios Tsimikas at the Vascular Biology Working Group global chapter meeting occurring concurrently with the American Heart Association, AHA, in Dallas, Texas. These data will also be presented at the AHA on Sunday, November 17 at 3:00 p.m. Central Time in the poster session titled 'Mechanisms and Regulation of Hepatic Lipid Metabolism.' In this study, healthy volunteers treated with ISIS-APO(a)Rx achieved dose-dependent reductions of up to 95% in lipoprotein, or Lp, an independent risk factor for coronary heart disease.

Rates

View Comments (0)